

References

I-201

1. Yukio A, Coelho T, Berk J, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. *Orphanet J Rare Dis.* 2013;8(31):1-18.
2. Adams D, Gonzalez-Duarte A, O'Riordan W, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379:11-21.
3. Adams D, Suhr O, Dyck P, et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. *BMC Neuro.* 2017;17:1-12.
4. Gonzalez-Duarte A, Lem-Carrillo M, & Cardenas-Soto K. Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy. 2013;20(4):221-225.
5. Benson M, Waddington-Cruz M, Berk J, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. *N Engl J Med.* 2018;379(1):22-31.
6. Tegsedi® (inotersen) injection, for subcutaneous use. [prescribing information] Akcea Therapeutics, Inc. Boston, MA. Revised 5/2021.
7. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT:CMT-0009(SR).
8. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. 2016.
9. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.
10. Solomon SD, Adams D, Kristen A et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. *Circulation.* 2019;139:431-443.
11. Coelho T, Adams D, Conceicao I, et al. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis. *Orphanet J Rare Dis.* 2020;15(1):179.
12. Adams D, Tournev I, Taylor M et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: A randomized clinical trial. *Amyloid.* 2023;30(1):1-9.
13. Inotersen In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 2, 2020.
14. Vutrisiran In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated July 6, 2022.

- 15.Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc.
Inotersen.
- 16.Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc.
Patisiran.
- 17.Clinical Pharmacology™ Compendium. 2023. Tampa FL: Gold Standard, Inc.
Vutrisiran.
- 18.Micromedex DrugDex Compendium®. 2023. Patisiran.
- 19.Micromedex DrugDex Compendium®. 2023. Inotersen.
- 20.Micromedex DrugDex Compendium®. 2023. Vutrisiran.
- 21.Tegsedi® (inotersen) injection, for subcutaneous use. [prescribing information]
Akcea Therapeutics, Inc. Boston, MA. Revised 6/2022.
- 22.Onpattro® (patisiran) lipid complex injection, for intravenous use [prescribing
information] Alnylam Pharmaceuticals, Inc., Cambridge, MA. Revised
01/2023.
- 23.Amvuttra™ (vutrisiran) injection, for subcutaneous use [prescribing
information] Alnylam Pharmaceuticals, Inc., Cambridge, MA. Revised 2/2023.